Based on the Biosyent Inc. stock forecast from 1 analysts, the average analyst target price for Biosyent Inc. is CAD 11.75 over the next 12 months. Biosyent Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Biosyent Inc. is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Biosyent Inc.’s stock price was CAD 11.70. Biosyent Inc.’s stock price has changed by +7.04% over the past week, +2.81% over the past month and +38.79% over the last year.
No recent analyst target price found for Biosyent Inc.
No recent average analyst rating found for Biosyent Inc.
Company Overview Biosyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada. Read Less
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance...Read More
Frequently Asked Questions About Biosyent Inc. (RX:CA) Stock
Based on ratings from 1 analysts Biosyent Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 1 buy, sell and hold ratings.
RX:CA stock's dividend yield is 1.65%.
Our analysis grades RX:CA stock's dividend yield at A+. This means that RX:CA stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSV exchange.
Based on this RX:CA may be a good dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for RX:CA is CAD 11.75 over the next 12 months. The maximum analyst target price is CAD 11.75 while the minimum anlayst target price is CAD 11.75.
RX:CA stock's Price/Earning ratio is 18.75.
Our analysis grades RX:CA stock's Price / Earning ratio at F. This means that RX:CA stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSV exchange.
Based on this RX:CA may be a overvalued for its sector.
The last closing price of RX:CA's stock was CAD 11.70.
The most recent market capitalization for RX:CA is CAD 0.13B.
Based on targets from 1 analysts, the average taret price for RX:CA is projected at CAD 11.75 over the next 12 months.
This means that RX:CA's stock price may go up by +0.43% over the next 12 months.
We can't find any ETFs which contains Biosyent Inc.'s stock.
As per our most recent records Biosyent Inc. has 0 Employees.
Biosyent Inc.'s registered address is 2476 Argentia Road, Mississauga, ON, Canada, L5N 6M1.
You can get more information about it from Biosyent Inc.'s website at https://www.biosyent.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Biosyent Inc. (RX:CA) Stock
Based on ratings from 1 analysts Biosyent Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 1 buy, sell and hold ratings.
RX:CA stock's dividend yield is 1.65%.
Our analysis grades RX:CA stock's dividend yield at A+. This means that RX:CA stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSV exchange.
Based on this RX:CA may be a good dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for RX:CA is CAD 11.75 over the next 12 months. The maximum analyst target price is CAD 11.75 while the minimum anlayst target price is CAD 11.75.
RX:CA stock's Price/Earning ratio is 18.75.
Our analysis grades RX:CA stock's Price / Earning ratio at F. This means that RX:CA stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSV exchange.
Based on this RX:CA may be a overvalued for its sector.
The last closing price of RX:CA's stock was CAD 11.70.
The most recent market capitalization for RX:CA is CAD 0.13B.
Based on targets from 1 analysts, the average taret price for RX:CA is projected at CAD 11.75 over the next 12 months.
This means that RX:CA's stock price may go up by +0.43% over the next 12 months.
We can't find any ETFs which contains Biosyent Inc.'s stock.
As per our most recent records Biosyent Inc. has 0 Employees.
Biosyent Inc.'s registered address is 2476 Argentia Road, Mississauga, ON, Canada, L5N 6M1.
You can get more information about it from Biosyent Inc.'s website at https://www.biosyent.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RX:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
